nab-Paclitaxel+carboplatin

DRUG2 trials

Sponsors

AstraZeneca, Shengjing Hospital

Conditions

Breast CancerNon-small Cell Lung Cancer NSCLC

Phase 2

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Active, not recruitingNCT03775486

AstraZenecaNon-small Cell Lung Cancer NSCLC

Start: 2018-12-21End: 2026-09-27Updated: 2026-02-10

Phase 3

Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT

RecruitingNCT04137653

Shengjing HospitalBreast Cancer

Start: 2021-07-19End: 2026-11-30Target: 1498Updated: 2021-07-20

Related Papers

Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.

2023-06-298 citations

Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial.

2022-08-1136 citations

ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2019-05-204 citations